Clinical Trial Update: A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating IBI362 in patients with obesity and heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fracti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Mildly Reduced Ejection Fraction
• Heart Failure with Preserved Ejection Fraction
• Obesity

Drugs mentioned

• IBI362

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF) | Phase 2 | Status: RECRUITING